{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:32:58Z","timestamp":1787506378938,"version":"build-2736575974"},"reference-count":44,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,27]],"date-time":"2020-03-27T00:00:00Z","timestamp":1585267200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ophtha.2020.03.031","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T02:46:05Z","timestamp":1585795565000},"page":"1360-1370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration"],"prefix":"10.1016","volume":"127","author":[{"given":"SriniVas R.","family":"Sadda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar Saleh","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth M.","family":"Marion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1733-6403","authenticated-orcid":false,"given":"Elizabeth","family":"Morgenthien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shamika","family":"Gune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva","family":"Balasubramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2020.03.031_bib1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","article-title":"Clinical classification of age-related macular degeneration","volume":"120","author":"Ferris","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ophtha.2007.03.008","article-title":"The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis","volume":"115","author":"Wong","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib3","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/IAE.0000000000001732","article-title":"Improving the age-related macular degeneration construct: a new classification system","volume":"38","author":"Spaide","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.03.031_bib4","doi-asserted-by":"crossref","DOI":"10.1167\/iovs.16-19969","article-title":"Optical coherence tomography and the development of antiangiogenic therapies in neovascular age-related macular degeneration","volume":"57","author":"Rosenfeld","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.03.031_bib5","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ophtha.2017.08.030","article-title":"Natural history of subclinical neovascularization in nonexudative age-related macular degeneration using swept-source OCT angiography","volume":"125","author":"de Oliveira Dias","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2020.03.031_bib7","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2020.03.031_bib8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib9","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.ophtha.2012.04.015","article-title":"Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial","volume":"119","author":"Chakravarthy","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib10","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2020.03.031_bib11","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2013.06.020","article-title":"Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial","volume":"120","author":"Kodjikian","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies","volume":"121","author":"Schmidt-Erfurth","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","article-title":"Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial","volume":"382","author":"Chakravarthy","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2020.03.031_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ophtha.2013.08.015","article-title":"Risk of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"121","author":"Grunwald","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.ophtha.2014.11.007","article-title":"Growth of geographic atrophy in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)","volume":"122","author":"Grunwald","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 years of Comparison of Age-Related Macular Degeneration Treatments Trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib17","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ophtha.2017.12.026","article-title":"Macular atrophy in the HARBOR study for neovascular age-related macular degeneration","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ophtha.2018.07.013","article-title":"Intralesional macular atrophy in anti\u2013vascular endothelial growth factor therapy for age-related macular degeneration in the IVAN trial","volume":"126","author":"Bailey","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib19","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","article-title":"Consensus definition for atrophy associated with age-related macular degeneration on OCT: Classification of Atrophy Report 3","volume":"125","author":"Sadda","year":"2018","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib20","article-title":"A\u00a0longitudinal SD-OCT analysis of macular atrophy in the HARBOR trial","volume":"59","author":"Sadda","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.03.031_bib21","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib22","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/IAE.0000000000001059","article-title":"Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy","volume":"36","author":"Abdelfattah","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.03.031_bib23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ophtha.2015.09.036","article-title":"Natural history of geographic atrophy progression secondary to age-related macular degeneration (Geographic Atrophy Progression Study)","volume":"123","author":"Schmitz-Valckenberg","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib24","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1097\/IAE.0000000000001766","article-title":"Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti-vascular endothelial growth factor therapy: an optical coherence tomographic angiography analysis","volume":"38","author":"Christenbury","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.03.031_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40942-015-0015-6","article-title":"Type 1 neovascularization may confer resistance to geographic atrophy amongst eyes treated for neovascular age-related macular degeneration","volume":"1","author":"Dhrami-Gavazi","year":"2015","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.ophtha.2020.03.031_bib26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2015.10.034","article-title":"Outcomes in eyes with retinal angiomatous proliferation in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)","volume":"123","author":"Daniel","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib27","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/IAE.0000000000000488","article-title":"Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography","volume":"35","author":"Nagiel","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.03.031_bib28","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/j.ophtha.2014.06.034","article-title":"Optical coherence tomography\u2013defined changes preceding the development of drusen-associated atrophy in age-related macular degeneration","volume":"121","author":"Wu","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1167\/iovs.14-14933","article-title":"Choroidal thickness in geographic atrophy secondary to age-related macular degeneration","volume":"56","author":"Lindner","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.03.031_bib30","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/IAE.0b013e3182993e09","article-title":"Analysis of the thickness and vascular layers of the choroid in eyes with geographic atrophy using spectral-domain optical coherence tomography","volume":"34","author":"Adhi","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2020.03.031_bib31","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.ophtha.2013.12.034","article-title":"Reticular pseudodrusen: a risk factor for geographic atrophy in fellow eyes of individuals with unilateral choroidal neovascularization","volume":"121","author":"Finger","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ophtha.2015.10.029","article-title":"Reticular pseudodrusen and their association with age-related macular degeneration: the Melbourne Collaborative Cohort Study","volume":"123","author":"Finger","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2020.03.031_bib33","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ajo.2006.11.041","article-title":"Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration","volume":"143","author":"Holz","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.03.031_bib34","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1167\/iovs.13-12474","article-title":"Reticular pseudodrusen in early age-related macular degeneration are associated with choroidal thinning","volume":"54","author":"Garg","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2020.03.031_bib35","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/ceo.13131","article-title":"Relationship between reticular pseudodrusen and choroidal thickness in intermediate age-related macular degeneration","volume":"46","author":"Ho","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.03.031_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","article-title":"Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation","volume":"159","author":"Cho","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.03.031_bib37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ajo.2019.04.037","article-title":"Quantitative assessment of choriocapillaris flow deficits in eyes with advanced age-related macular degeneration versus healthy eyes","volume":"205","author":"Alagorie","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.03.031_bib38","first-page":"8125267","article-title":"Choriocapillaris loss in advanced age-related macular degeneration","volume":"2018","author":"Moreira-Neto","year":"2018","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.03.031_bib39","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/bjophthalmol-2018-312643","article-title":"Choriocapillaris impairment around the atrophic lesions in patients with geographic atrophy: a swept-source optical coherence tomography angiography study","volume":"103","author":"Nassisi","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2020.03.031_bib40","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.oret.2019.01.024","article-title":"Correlations between choriocapillaris flow deficits around geographic atrophy and enlargement rates based on swept-source OCT imaging","volume":"3","author":"Thulliez","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.ophtha.2020.03.031_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212563","article-title":"Choriocapillaris flow impairment surrounding geographic atrophy correlates with disease progression","volume":"14","author":"Nassisi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2020.03.031_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40662-018-0118-x","article-title":"Choriocapillaris changes in dry age-related macular degeneration and geographic atrophy: a review","volume":"5","author":"Arya","year":"2018","journal-title":"Eye Vis (Lond)"},{"key":"10.1016\/j.ophtha.2020.03.031_bib43","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jcp.22129","article-title":"Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells","volume":"224","author":"Miki","year":"2010","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.ophtha.2020.03.031_bib44","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.oret.2018.04.009","article-title":"Atrophy in neovascular age-related macular degeneration: Age-Related Eye Disease Study 2 report number 15","volume":"2","author":"Domalpally","year":"2018","journal-title":"Ophthalmol Retina"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020303158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642020303158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:09:11Z","timestamp":1758982151000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642020303158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0161642020303158"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.031","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2020.03.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of OphthalmologyThis is an open access article under the CC BY-NC-ND license (<inter-ref xlink: href=http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/>http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/<\/inter-ref>).","name":"copyright","label":"Copyright"}]}}